Personalised Medicine: Milestone In The Therapy Control Of Humanised Antibodies
July 30th, 2007 by 
Barry - Admin BioPharmArena
CENiMED GmbH, BioTeZ Berlin-Buch GmbH and Invitek Gesellschaft für Biotechnik & Biodesign mbH (company for biotechnology and bio-design) announce their cooperation in the development, production and marketing of Recovery-ELISAs for therapy control of a new group of therapeutics, the so called humanised antibodies.
Humanised antibodies offer unforeseen potentialities in cancer therapy, e. g. for the treatment of mamma carcinoma. Previous therapy control methods, however, could not avoid overdoses which had caused adverse reactions with the patients. Recovery-ELISA (R-ELISA) is an innovative, patented ELISA technique for the determination of the exact efficacy concentration of the therapeutic antibodies and the therapy control. The automation of this technique will be established by a renowned platform manufacturer and then will be made available for the patients and the pharmaceutical industry.
Posted in News, Technologies in the BioPharmaceutical Industry, Research and Development | 